Also Read: Sanofi’s Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows. Sarclisa is the first anti-CD38 therapy in combination with standard-of-care VRd ...

Sanofi’s SNY stock has gained 22.7% in the past three months compared with an increase of 2.9% for the industry. The stock has also outperformed the sector and the S&P 500 index as seen in the ...

Pakistan Stock Exchange’s benchmark KSE-100 index gained 1.1% to close just shy of the previous record of 81,865.10, after touching a new high earlier in the day.

Russia expressed support Wednesday for Pakistan's entry into the BRICS intergovernmental group of major emerging economies from the Global South. Russian Deputy Prime Minister Alexei Overchuk made ...

Meanwhile, in another patent suit, Panacea Biotec on Tuesday announced it reached a settlement agreement with Sanofi Healthcare India over patent infringement litigation for a fully liquid ...

Panacea Biotec has resolved a patent infringement lawsuit with Sanofi Healthcare concerning its EasySix hexavalent vaccine. Under the settlement, Sanofi will refrain from launching its Shan6 ...

Panacea Biotec has settled a patent infringement case with Sanofi Healthcare India over a hexavalent vaccine. Sanofi will not launch its Shan6 vaccine in India and will withdraw its opposition to ...

South Africans need to be in the know if we want to create a prosperous future. News24 has kept the country informed for 25 years, and we're about to enter a new chapter of fearless journalism. Join ...

Former Zantac makers GSK, Pfizer, Sanofi and Boehringer Ingelheim are facing about 4,000 claims in California state court and about 2,000 in various other state courts around the country.

Panacea Biotec share price was locked in upper circuit in Tuesday's trading session after the company announced that it has entered into a settlement agreement with Sanofi Healthcare India over ...

Shares of Panacea Biotec Ltd. hit the 5% upper circuit to touch the highest level in over three years on Tuesday as the company reached a settlement agreement with Sanofi Healthcare India Pvt. over a ...

BMS is ending its $150m deal with Immatics to help develop its bispecific. Image credit: Getty Images / sesame. Immatics has been left with the full rights to develop a bispecific molecule after its ...